• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

5年间患有该基因变异的小儿患者早期症状发作和进展的前瞻性特征:来自法布里病儿童前瞻性多中心自然史研究(Fabry MOPPet Study)的纵向数据

Prospective characterization of early symptom onset and progression in young pediatric patients with variants in the gene across 5 years: Longitudinal data from the Fabry MOPPet Study.

作者信息

Laney D A, Houde M F, Foley A L, Peck D S, Atherton A M, Manwaring L P, Grange D K, Heese B A, Holida M D, Quillin A L, Vinson R, Auray-Blais C, Hopkin R J

机构信息

School of Medicine, Department of Human Genetics, Emory University, Atlanta, GA.

Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN.

出版信息

Genet Med Open. 2024 Sep 10;2:101891. doi: 10.1016/j.gimo.2024.101891. eCollection 2024.

DOI:10.1016/j.gimo.2024.101891
PMID:39669636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11613563/
Abstract

PURPOSE

This prospective, longitudinal study was designed to determine the natural history of Fabry disease (FD) in early pediatric patients across the disease spectrum.

METHODS

In this observational study of children under 5 years of age with variants in the  gene, prospective phenotypic and urinary biomarker data were collected annually over 5 years.

RESULTS

The study population included 40 participants (35 male, 5 female) with variants including 15 with classic pathogenic variants (CFD), 6 with nonclassic pathogenic variants (NFD), and 19 with a variant of uncertain significance. The most common first symptoms reported were in participants with CFD and included gastrointestinal symptoms (13/15), heat intolerance (13/15), reduced sweating after previously sweating normally (6/15), and neuropathic pain/uncomfortable feet/hands (3/15). Mapping symptom onset and progression reveals a consistent pattern of frequency and severity occurring in the first years of life and beginning at an average age of 23.4 months (range 11-32 months) in males with CFD. Participants with nonclassic pathogenic variants and variant of uncertain significance did not exhibit consistency in symptom onset or progression during the study period.

CONCLUSION

This study highlights the onset and pattern of progression of the earliest Fabry-related symptoms in children with CFD.

摘要

目的

本前瞻性纵向研究旨在确定疾病谱中早期儿科患者法布里病(FD)的自然病史。

方法

在这项针对5岁以下携带该基因变异儿童的观察性研究中,在5年时间里每年收集前瞻性表型和尿液生物标志物数据。

结果

研究人群包括40名参与者(35名男性,5名女性),携带的变异包括15名携带经典致病变异(CFD)、6名携带非经典致病变异(NFD)以及19名携带意义未明变异。报告的最常见首发症状出现在CFD参与者中,包括胃肠道症状(13/15)、不耐热(13/15)、既往正常出汗后出汗减少(6/15)以及神经性疼痛/足部/手部不适(3/15)。绘制症状发作和进展情况显示,在生命的最初几年出现了频率和严重程度一致的模式,CFD男性患者平均发病年龄为23.4个月(范围11 - 32个月)。非经典致病变异和意义未明变异的参与者在研究期间症状发作或进展情况不一致。

结论

本研究突出了CFD患儿最早出现的法布里病相关症状的发作情况和进展模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/52ab1c032885/figs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/5001762adb59/gr1ab.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/0f8bad962247/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/f481890859c3/figs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/473e8df9062f/figs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/52ab1c032885/figs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/5001762adb59/gr1ab.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/0f8bad962247/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/f481890859c3/figs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/473e8df9062f/figs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84f0/11613563/52ab1c032885/figs3.jpg

相似文献

1
Prospective characterization of early symptom onset and progression in young pediatric patients with variants in the gene across 5 years: Longitudinal data from the Fabry MOPPet Study.5年间患有该基因变异的小儿患者早期症状发作和进展的前瞻性特征:来自法布里病儿童前瞻性多中心自然史研究(Fabry MOPPet Study)的纵向数据
Genet Med Open. 2024 Sep 10;2:101891. doi: 10.1016/j.gimo.2024.101891. eCollection 2024.
2
Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry.在年轻的急性脑卒中患者中 Fabry 病和 GLA 变异体的流行情况:扩大筛查范围的挑战。意大利 Fabry 脑卒中登记研究。
J Neurol Sci. 2024 Feb 15;457:122905. doi: 10.1016/j.jns.2024.122905. Epub 2024 Jan 24.
3
The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.应用 NGS 技术的俄罗斯全国性肥厚型心肌病患者筛查项目中 1009 例非相关患者中 Fabry 病的患病率。
Orphanet J Rare Dis. 2022 May 16;17(1):199. doi: 10.1186/s13023-022-02319-4.
4
Enhancing Fabry disease screening and diagnostic efficiency: Integration of enzyme, biomarker, and next-generation sequencing testing.提高法布里病的筛查和诊断效率:酶、生物标志物和新一代测序检测的整合
Mol Genet Metab. 2025 May;145(1):109082. doi: 10.1016/j.ymgme.2025.109082. Epub 2025 Mar 15.
5
Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.巴西法布里病患者的风湿性表现发生率较高且诊断延迟。
Adv Rheumatol. 2020 Jan 6;60(1):7. doi: 10.1186/s42358-019-0111-7.
6
Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease.法布里病患者报告结局(FD-PRO)在评估法布里病症状严重程度方面显示出强大的测量特性。
Mol Genet Metab Rep. 2021 Nov 19;29:100824. doi: 10.1016/j.ymgmr.2021.100824. eCollection 2021 Dec.
7
Frequency of Fabry disease in a juvenile idiopathic arthritis cohort.法布瑞病在幼年特发性关节炎队列中的频率。
Pediatr Rheumatol Online J. 2021 Jun 12;19(1):91. doi: 10.1186/s12969-021-00563-9.
8
The Identification of a Novel Pathogenic Variant of the Gene Associated with a Classic Phenotype of Anderson-Fabry Disease: A Clinical and Molecular Study.与经典型安德森-法布里病表型相关基因的新型致病变异的鉴定:一项临床与分子研究
Int J Mol Sci. 2025 Jan 8;26(2):470. doi: 10.3390/ijms26020470.
9
Use of a rare disease registry for establishing phenotypic classification of previously unassigned variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup.利用罕见病登记处对先前未分配的变异体进行表型分类:多学科法布里病基因型-表型工作组的共识分类系统。
J Med Genet. 2020 Aug;57(8):542-551. doi: 10.1136/jmedgenet-2019-106467. Epub 2020 Mar 11.
10
Newborn screening for Fabry disease in the north-west of Spain.西班牙西北部法布里病的新生儿筛查。
Eur J Pediatr. 2017 Aug;176(8):1075-1081. doi: 10.1007/s00431-017-2950-8. Epub 2017 Jun 23.

引用本文的文献

1
Fabry disease in females: organ involvement and clinical outcomes compared with the general population (103/150 characters).女性法布里病:与普通人群相比的器官受累情况及临床结局(103/150字符)
Orphanet J Rare Dis. 2025 Aug 13;20(1):433. doi: 10.1186/s13023-025-03922-x.

本文引用的文献

1
Newborn Screening for Fabry Disease: Current Status of Knowledge.法布里病的新生儿筛查:知识现状
Int J Neonatal Screen. 2023 Jun 5;9(2):31. doi: 10.3390/ijns9020031.
2
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.30 岁前接受阿加糖酶β治疗的法布瑞病年轻患者的临床结局:法布瑞登记研究的分析。
Mol Genet Metab. 2023 Feb;138(2):106967. doi: 10.1016/j.ymgme.2022.106967. Epub 2022 Nov 30.
3
Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes.
麦格司他治疗 Fabry 相关临床事件(包括肾脏、心脏和脑血管结局)的长期多系统疗效。
J Med Genet. 2023 Jul;60(7):722-731. doi: 10.1136/jmg-2022-108669. Epub 2022 Dec 21.
4
Newborn screening for Fabry disease in Oregon: Approaching the iceberg of A143T and variants of uncertain significance.俄勒冈州法布雷病的新生儿筛查:即将揭示 A143T 及意义不明的变异体冰山一角。
Am J Med Genet C Semin Med Genet. 2022 Jun;190(2):206-214. doi: 10.1002/ajmg.c.31998. Epub 2022 Sep 26.
5
Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry.法布里病结局调查 20 年:全球患者注册研究的见解、成就和经验教训。
Orphanet J Rare Dis. 2022 Jun 20;17(1):238. doi: 10.1186/s13023-022-02392-9.
6
Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up.法布里病的生物标志物。对临床诊断和随访的意义。
J Clin Med. 2021 Apr 13;10(8):1664. doi: 10.3390/jcm10081664.
7
Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.基线左心室肥厚和肾功能下降对接受阿加糖酶α治疗的法布病患者心血管和肾脏结局的影响:一项法布病结局调查研究。
Clin Ther. 2020 Dec;42(12):2321-2330.e0. doi: 10.1016/j.clinthera.2020.10.007. Epub 2020 Nov 17.
8
MOLGENIS research: advanced bioinformatics data software for non-bioinformaticians.MOLGENIS 研究:面向非生物信息学家的高级生物信息学数据软件。
Bioinformatics. 2019 Mar 15;35(6):1076-1078. doi: 10.1093/bioinformatics/bty742.
9
Fabry disease revisited: Management and treatment recommendations for adult patients.重新审视法布里病:成年患者的管理和治疗建议。
Mol Genet Metab. 2018 Apr;123(4):416-427. doi: 10.1016/j.ymgme.2018.02.014. Epub 2018 Feb 28.
10
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.接受阿加糖酶β酶替代疗法治疗的法布里病男性和女性患者发生严重临床事件的风险因素:来自法布里病注册研究的数据。
Mol Genet Metab. 2016 Sep;119(1-2):151-9. doi: 10.1016/j.ymgme.2016.06.007. Epub 2016 Jun 13.